PMC:7405836 / 93937-94108 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T330","span":{"begin":13,"end":17},"obj":"Body_part"},{"id":"T331","span":{"begin":95,"end":102},"obj":"Body_part"}],"attributes":[{"id":"A330","pred":"fma_id","subj":"T330","obj":"http://purl.org/sig/ont/fma/fma67122"},{"id":"A331","pred":"fma_id","subj":"T331","obj":"http://purl.org/sig/ont/fma/fma67257"}],"text":"By employing mRNA vaccine platform technology, a vaccine candidate expressing SARS-CoV-2 spike protein is likely to go through clinical testing in the coming months (180)."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T872","span":{"begin":78,"end":86},"obj":"Disease"},{"id":"T873","span":{"begin":78,"end":82},"obj":"Disease"}],"attributes":[{"id":"A872","pred":"mondo_id","subj":"T872","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"},{"id":"A873","pred":"mondo_id","subj":"T873","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"By employing mRNA vaccine platform technology, a vaccine candidate expressing SARS-CoV-2 spike protein is likely to go through clinical testing in the coming months (180)."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T863","span":{"begin":47,"end":48},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T864","span":{"begin":136,"end":143},"obj":"http://purl.obolibrary.org/obo/UBERON_0000473"}],"text":"By employing mRNA vaccine platform technology, a vaccine candidate expressing SARS-CoV-2 spike protein is likely to go through clinical testing in the coming months (180)."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T29073","span":{"begin":95,"end":102},"obj":"Chemical"}],"attributes":[{"id":"A15872","pred":"chebi_id","subj":"T29073","obj":"http://purl.obolibrary.org/obo/CHEBI_36080"}],"text":"By employing mRNA vaccine platform technology, a vaccine candidate expressing SARS-CoV-2 spike protein is likely to go through clinical testing in the coming months (180)."}

{"project":"LitCovid-sentences","denotations":[{"id":"T653","span":{"begin":0,"end":171},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"By employing mRNA vaccine platform technology, a vaccine candidate expressing SARS-CoV-2 spike protein is likely to go through clinical testing in the coming months (180)."}

{"project":"LitCovid-PubTator","denotations":[{"id":"2551","span":{"begin":89,"end":94},"obj":"Gene"},{"id":"2556","span":{"begin":78,"end":88},"obj":"Species"}],"attributes":[{"id":"A2551","pred":"tao:has_database_id","subj":"2551","obj":"Gene:43740568"},{"id":"A2556","pred":"tao:has_database_id","subj":"2556","obj":"Tax:2697049"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"By employing mRNA vaccine platform technology, a vaccine candidate expressing SARS-CoV-2 spike protein is likely to go through clinical testing in the coming months (180)."}